Cyclophosphamide trials for Breast Neoplasms

All Cyclophosphamide trials · All Breast Neoplasms trials

Phase breakdown

Recruiting trials studying Cyclophosphamide for Breast Neoplasms

• A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
  NCT06966700 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 325 locations
• Phase I Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes as Neoadjuvant Therapy for HER2-Negative Breast Cancer
  NCT06121570 · Phase: Phase 1 · Ages: 18 Years to 70 Years · Sex: Female · 1 location
• Phase I Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes for Advanced HER2-Negative Breast Cancer
  NCT06121557 · Phase: Phase 1 · Ages: 18 Years to 70 Years · Sex: Female · 1 location
• Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes as Neoadjuvant Therapy for HER2-Negative Breast Cancer
  NCT05981014 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 70 Years · Sex: Female · 1 location
• Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes for Advanced HER2-Negative Breast Cancer
  NCT05981001 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 70 Years · Sex: Female · 1 location
• Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)
  NCT06797635 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 17 locations
• Trilaciclib in Patients With Early-Stage HR-negative Breast Cancer Receiving Adjuvant Chemotherapy
  NCT05978648 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location

Common questions

How many trials study Cyclophosphamide for Breast Neoplasms?

7 recruiting trials.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.